|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||121.55 - 121.55|
|52 Week Range||87.77 - 142.75|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Phase 1 Clinical Study Expected to Start in Q4 2020 PLANEGG & MUNICH GERMANY AND SHANGHAI, CHINA / ACCESSWIRE / September 17, 2020 / MorphoSys AG (FSE:MOR)(Prime Standard Segment, MDAX & TecDAX; (NASDAQ:MOR) and I-Mab (NASDAQ:IMAB) today jointly announced that the U.
Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.
Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas